Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 16/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 11/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.45 |
| ▸ | PI4KA | P42356 | 4/20 | 0.42 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.42 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.42 |
| ▸ | AHCY | P23526 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2980005 | 0.79 | ADORA2A (0.64) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL23679559 | 0.79 | ADORA2A (0.64) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL29280561 | 0.79 | ADORA2A (0.46) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL27635785 | 0.75 | CYP1A2 (0.45) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL5732265 | 0.72 | ADORA2A (0.69) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL5731471 | 0.71 | ADORA2A (0.70) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL1914306 | 0.70 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL2342091 | 0.68 | ADORA2A (0.60) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL5732110 | 0.68 | ADORA2A (0.53) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL5732048 | 0.68 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BADORA3PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210154316-A1 | Immunoconjugates | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154316-A1 | Immunoconjugates | FCGR3B, FCGR2A, FCGR1A | ADORA2A 2245/4885ADORA1 867/4885ADORA2B 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.